Frontlight ResearchEarly access
TerminatedPhase 1
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
Key facts
- Who runs it
- Eureka Therapeutics Inc.
- Where
- Duarte and Westwood, United StatesSee the 2 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 8 people enrolled
- Started
- 14 Apr 2021
- Ended
- 30 Aug 2024
- Type of study
- Interventional
- Treatments tested
- ET140203 autologous T cell product
- Record updated
- 8 September 2025
- Why it stopped
- The trial was intended to be a Phase 1/2 trial, but the sponsor terminated the trial prior to moving to Phase 2 to direct efforts to the pediatric study (ARYA-2) for this product.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (18)Hide the full registry criteria
Who can take part
- Histologically confirmed HCC with serum AFP >100ng/ml at time of screening and following most current line of therapy OR radiographic diagnosis of HCC with serum AFP >400ng/ml at time of screening and following most current line of therapy
- Metastatic or locally advanced, unresectable HCC
- Must have failed or not tolerated at least two (2) different anti-HCC systemic agents
- Molecular Human Leukocyte Antigen ("HLA") class I allele typing confirms participant carries at least one HLA-A2 allele
- Life expectancy of at least 4 months
- Karnofsky Performance Scale greater than or equal to 70
- At least 1 measurable lesion on imaging by RECIST
- Child-Pugh A6 or better
- Absolute neutrophil count greater than or equal to 1,500/mm\^3
- Platelet count greater than or equal to 75,000/mm\^3
Who cannot take part
- Clinically significant cardiac disease
- Clinically significant pre-existing illness or active infection
- Active autoimmune disease requiring therapy
- History of organ transplant
- Active malignancy other than HCC with the exception of cholangiocarcinoma (CCA) or any malignancy with an expected survival ≥ 3 years without any treatment (exception: hormone/androgen-deprivation therapy) and without any organ involvement
- Clinically significant Central Nervous System (CNS) or neural dysfunction
- Compromised circulation in portal vein, hepatic vein, or vena cava due to obstruction
- Advanced HCC involving greater than 50% of the liver
Where in United States
- City of Hope Medical CenterDuarte, United States
- Kansas University Medical CenterWestwood, United States
About the trial
What the trial wants to find out
Open-label, dose escalation, multi-center, Phase I / II study to assess the safety of an autologous T-cell product (ET140203) in adult subjects with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive advanced hepatocellular carcinoma (HCC).
The group in the trial
- ET140203 TCellsTreatment being tested
ET140203 T Cells
Treatment: ET140203 autologous T cell product
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-1)
- Record updated
- 8 September 2025